Chemomab Therapeutics (CMMB) Current Leases (2019 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Current Leases came in at $113000.0 in Q1 2025, up 2.73% YoY from $110000.0 in Q1 2024, and down 1.74% on a QoQ basis from $115000.0 in Q4 2024.
Chemomab Therapeutics (CMMB) Current Leases (2019 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 7 years of Current Leases data on file, last reported at $113000.0 in Q1 2025.
- Quarterly Current Leases rose 2.73% year-over-year to $113000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $113000.0 (up 2.73% YoY) and the FY2024 annual result came in at $115000.0, up 51.32% from the prior year.
- Current Leases declined to $113000.0 in Q1 2025, from $115000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $132000.0 in Q2 2022 to a low of $61000.0 in Q3 2021.
- A 5-year average of $104000.0 and a median of $110000.0 in 2024 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2021 — Current Leases plunged 64.74% — and 2022, when it jumped 106.56%.
- Tracing CMMB's Current Leases over 5 years: stood at $106000.0 in 2021, then grew by 16.04% to $123000.0 in 2022, then sank by 38.21% to $76000.0 in 2023, then soared by 51.32% to $115000.0 in 2024, then slipped by 1.74% to $113000.0 in 2025.
- The last three Current Leases figures came in at $113000.0 (Q1 2025), $115000.0 (Q4 2024), and $112000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | - |
| 10 | Chemomab Therapeutics | 13.20 Mn | 2.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 113,000.00 |
| Dec 31, 2024 | 115,000.00 |
| Sep 30, 2024 | 112,000.00 |
| Jun 30, 2024 | 109,000.00 |
| Mar 31, 2024 | 110,000.00 |
| Dec 31, 2023 | 76,000.00 |
| Sep 30, 2023 | 105,000.00 |
| Jun 30, 2023 | 108,000.00 |
| Mar 31, 2023 | 115,000.00 |
| Dec 31, 2022 | 123,000.00 |
| Sep 30, 2022 | 126,000.00 |
| Jun 30, 2022 | 132,000.00 |
| Mar 31, 2022 | 116,000.00 |
| Dec 31, 2021 | 106,000.00 |
| Sep 30, 2021 | 61,000.00 |
| Jun 30, 2021 | 72,000.00 |
| Mar 31, 2021 | 69,000.00 |
| Dec 31, 2020 | 70,000.00 |
| Sep 30, 2020 | 173,000.00 |
| Jun 30, 2020 | 168,000.00 |